flucytosine has been researched along with Benign Neoplasms, Brain in 49 studies
Flucytosine: A fluorinated cytosine analog that is used as an antifungal agent.
flucytosine : An organofluorine compound that is cytosine that is substituted at position 5 by a fluorine. A prodrug for the antifungal 5-fluorouracil, it is used for the treatment of systemic fungal infections.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Temozolomide (TMZ) with radiation is the most frequently used first-line treatment for patients with glioblastoma, the most common and aggressive form of primary brain cancer in adults." | 7.79 | Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. ( Espinoza, FL; Gruber, HE; Gunzburg, W; Hlavaty, J; Huang, TT; Ibañez, CE; Jolly, DJ; Kasahara, N; Martin, B; Ostertag, D; Pertschuk, D; Petznek, H; Robbins, JM; Rodriguez-Aguirre, M, 2013) |
| "Lomustine is a treatment option for patients with high-grade glioma." | 5.43 | Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. ( Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016) |
| "5-Fluorouracil (5-FU) is a potent antimetabolite used for chemotherapy of gastrointestinal (GI), breast, and head and neck malignancies." | 5.31 | Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. ( Buchsbaum, DJ; Gillespie, GY; Miller, CR; Williams, CR, 2002) |
| " Temozolomide (TMZ) with radiation is the most frequently used first-line treatment for patients with glioblastoma, the most common and aggressive form of primary brain cancer in adults." | 3.79 | Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model. ( Espinoza, FL; Gruber, HE; Gunzburg, W; Hlavaty, J; Huang, TT; Ibañez, CE; Jolly, DJ; Kasahara, N; Martin, B; Ostertag, D; Pertschuk, D; Petznek, H; Robbins, JM; Rodriguez-Aguirre, M, 2013) |
| "Since neural progenitor cells can engraft stably into brain tumors and differentiate along the neuronal and glial line, we tested the hypothesis that transplanted cytosine deaminase (CD)-expressing ST14A cells (an immortalized neural progenitor cell line) can convert locally 5-fluorocytosine (5-FC) into 5-fluorouracil (5-FU) and produce a regression of glioma tumors." | 3.72 | Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy. ( Barresi, V; Belluardo, N; Cattaneo, E; Condorelli, DF; Mudò, G; Sipione, S, 2003) |
| "In this study, we investigated the feasibility of a double-suicide gene/prodrug therapy, involving direct introduction of the herpes simplex virus Type 1 thymidine kinase (TK) gene and the Escherichia coli cytosine deaminase (CD) gene, via a recombinant adenoviral vector, and ganciclovir (GCV) and/or 5-fluorocytosine (5-FC) treatment, in a rat C6 glioma model." | 3.70 | Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma. ( Chang, JW; Chung, SS; Kim, E; Kim, JH; Lee, H; Lee, Y, 2000) |
| "Glioblastoma and anaplastic astrocytoma are two of the most aggressive and common glioma malignancies in adults." | 2.61 | Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma. ( Adamson, DC; Philbrick, BD, 2019) |
| "Lomustine is a treatment option for patients with high-grade glioma." | 1.43 | Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models. ( Gruber, HE; Huang, TT; Ibañez, CE; Jolly, DJ; Lopez Espinoza, F; Mendoza, D; Robbins, JM; Yagiz, K, 2016) |
| " Survival benefit is dose dependent for both vector and 5-FC, and as few as 4 cycles of 5-FC dosing after Toca 511 therapy provides significant survival advantage." | 1.38 | Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector. ( Amundson, KK; Buckley, T; Burnett, R; Chen, CI; Daublebsky, V; Galvão da Silva, AP; Gruber, HE; Gunzburg, W; Hlavaty, J; Ibañez, CE; Jolly, DJ; Kasahara, N; Lin, AH; Lopez Espinoza, F; Martin, B; Ostertag, D; Perez, OD; Pettersson, PL; Robbins, JM; Valenta, DT, 2012) |
| "The majority of brain metastases result from lung cancer, but the metastatic mechanism remains unclear." | 1.38 | Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties. ( Cho, MH; Choi, KC; Kim, SU; Kim, YB; Lee, HJ; Yi, BR, 2012) |
| "Immunohistochemistry of rat brain tumors inoculated with MSC-EGFP showed intratumoral distribution of MSC-EGFP." | 1.38 | Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma. ( Date, I; Hamada, H; Ichikawa, T; Inoue, S; Kambara, H; Kosaka, H; Kurozumi, K; Maruo, T; Nakamura, K, 2012) |
| "In a novel experimental brain metastases model, intravenously administered F3 cells migrated near lung cancer metastatic lesions, which were induced by the injection of lung cancer cells via the intracarotid artery." | 1.38 | Neural stem cell-based dual suicide gene delivery for metastatic brain tumors. ( Ito, M; Iwami, K; Kim, SU; Kinjo, S; Lee, HJ; Momota, H; Motomura, K; Natsume, A; Nishimira, Y; Ohka, F; Ohno, M; Wakabayashi, T; Wang, C, 2012) |
| "In vivo, MDA-MB-435 human breast cancer cells were implanted into the brain of immune-deficient mouse stereotactically, and F3." | 1.35 | Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases. ( Jin, J; Jo, MY; Joo, KM; Kang, BG; Kim, MH; Kim, SU; Lee, SJ; Nam, DH; Park, IH; Shin, JY, 2009) |
| "The infection of RG2 brain tumors with RCR-CD and their subsequent treatment with 5-FC significantly prolonged survival compared with that in animals with RG2 transduced tumors treated with PBS." | 1.33 | Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model. ( Chen, TC; Kasahara, N; Kershaw, AD; Klatzmann, D; Solly, SK; Tai, CK; Wang, W, 2006) |
| "Rats bearing 9 L brain tumors were treated with an intratumoral injection of AdexCACD followed by intraperitoneal administration of 5-FC." | 1.31 | In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus. ( Adachi, Y; Furuta, T; Hamada, H; Ichikawa, T; Matsumoto, K; Ohmoto, T; Ono, Y; Tamiya, T; Yoshida, Y, 2000) |
| " New interim measures of therapeutic response would be particularly useful in the development of cancer chemosensitization gene therapy by facilitating optimization of gene transfer protocols and prodrug dosing schedules." | 1.31 | Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy. ( Chenevert, TL; Hamstra, DA; Jonas, SJ; Rehemtulla, A; Rice, DJ; Ross, BD; Stegman, LD; Stout, KL, 2000) |
| "5-Fluorouracil (5-FU) is a potent antimetabolite used for chemotherapy of gastrointestinal (GI), breast, and head and neck malignancies." | 1.31 | Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas. ( Buchsbaum, DJ; Gillespie, GY; Miller, CR; Williams, CR, 2002) |
| " In vitro studies showed that 5-FC combined with CDase induced significant growth-inhibitory effects on the cultured glioma cells." | 1.27 | Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules. ( Ito, T; Katsuragi, T; Kawamoto, K; Kawamura, Y; Matsumura, H; Nishiyama, T; Ohyama, A; Sakai, T; Yamamoto, N, 1985) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 2 (4.08) | 18.7374 |
| 1990's | 5 (10.20) | 18.2507 |
| 2000's | 15 (30.61) | 29.6817 |
| 2010's | 24 (48.98) | 24.3611 |
| 2020's | 3 (6.12) | 2.80 |
| Authors | Studies |
|---|---|
| Chen, SH | 1 |
| Sun, JM | 1 |
| Chen, BM | 1 |
| Lin, SC | 1 |
| Chang, HF | 1 |
| Collins, S | 1 |
| Chang, D | 1 |
| Wu, SF | 1 |
| Lu, YC | 1 |
| Wang, W | 2 |
| Chen, TC | 3 |
| Kasahara, N | 10 |
| Wang, HE | 1 |
| Tai, CK | 3 |
| Accomando, WP | 1 |
| Rao, AR | 2 |
| Hogan, DJ | 2 |
| Newman, AM | 1 |
| Nakao, A | 1 |
| Alizadeh, AA | 1 |
| Diehn, M | 1 |
| Diago, OR | 2 |
| Gammon, D | 2 |
| Haghighi, A | 1 |
| Gruber, HE | 8 |
| Jolly, DJ | 8 |
| Ostertag, D | 6 |
| Cloughesy, TF | 2 |
| Petrecca, K | 1 |
| Walbert, T | 2 |
| Butowski, N | 1 |
| Salacz, M | 1 |
| Perry, J | 1 |
| Damek, D | 1 |
| Bota, D | 1 |
| Bettegowda, C | 1 |
| Zhu, JJ | 1 |
| Iwamoto, F | 1 |
| Placantonakis, D | 1 |
| Kim, L | 1 |
| Elder, B | 1 |
| Kaptain, G | 1 |
| Cachia, D | 1 |
| Moshel, Y | 1 |
| Brem, S | 1 |
| Piccioni, D | 2 |
| Landolfi, J | 2 |
| Chen, CC | 2 |
| Gruber, H | 1 |
| Hogan, D | 1 |
| Accomando, W | 2 |
| Montellano, TT | 1 |
| Kheoh, T | 2 |
| Kabbinavar, F | 1 |
| Vogelbaum, MA | 2 |
| Mitchell, LA | 1 |
| Lopez Espinoza, F | 3 |
| Mendoza, D | 2 |
| Kato, Y | 2 |
| Inagaki, A | 2 |
| Hiraoka, K | 1 |
| Robbins, JM | 6 |
| Elder, JB | 1 |
| Bloomfield, S | 1 |
| Carter, B | 1 |
| Kalkanis, SN | 1 |
| Kesari, S | 1 |
| Lai, A | 1 |
| Lee, IY | 1 |
| Liau, LM | 1 |
| Mikkelsen, T | 1 |
| Nghiemphu, P | 1 |
| Das, A | 1 |
| Philbrick, BD | 1 |
| Adamson, DC | 1 |
| Kazlauskas, A | 1 |
| Darinskas, A | 1 |
| Meškys, R | 1 |
| Tamašauskas, A | 1 |
| Urbonavičius, J | 1 |
| Yin, D | 1 |
| Zhai, Y | 1 |
| Ibanez, CE | 5 |
| Kells, AP | 1 |
| Forsayeth, J | 1 |
| Bankiewicz, KS | 1 |
| Hickey, MJ | 1 |
| Malone, CC | 1 |
| Erickson, KL | 1 |
| Lin, A | 1 |
| Soto, H | 1 |
| Ha, ET | 1 |
| Kamijima, S | 1 |
| Takahashi, M | 1 |
| Mueller, BM | 1 |
| Kruse, CA | 1 |
| Kang, W | 1 |
| Seol, HJ | 1 |
| Seong, DH | 1 |
| Kim, J | 1 |
| Kim, Y | 2 |
| Kim, SU | 5 |
| Nam, DH | 3 |
| Joo, KM | 3 |
| Niu, J | 1 |
| Xing, C | 1 |
| Yan, C | 1 |
| Liu, H | 1 |
| Cui, Y | 1 |
| Peng, H | 1 |
| Chen, Y | 1 |
| Li, D | 1 |
| Jiang, C | 1 |
| Li, N | 1 |
| Yang, H | 2 |
| Parry, PV | 1 |
| Engh, JA | 1 |
| Huang, TT | 3 |
| Hlavaty, J | 3 |
| Espinoza, FL | 2 |
| Martin, B | 3 |
| Petznek, H | 2 |
| Rodriguez-Aguirre, M | 1 |
| Gunzburg, W | 2 |
| Pertschuk, D | 2 |
| Altaner, C | 2 |
| Altanerova, V | 2 |
| Cihova, M | 2 |
| Ondicova, K | 2 |
| Rychly, B | 2 |
| Baciak, L | 1 |
| Mravec, B | 2 |
| Parab, S | 1 |
| Burnett, R | 2 |
| Diago, O | 1 |
| Hofman, FM | 1 |
| Yagiz, K | 1 |
| Strebe, JK | 1 |
| Lubin, JA | 1 |
| Kuo, JS | 1 |
| Park, IH | 1 |
| Shin, JY | 1 |
| Jin, J | 2 |
| Kang, BG | 1 |
| Kim, MH | 1 |
| Lee, SJ | 2 |
| Jo, MY | 2 |
| Breton, E | 1 |
| Goetz, C | 1 |
| Kintz, J | 1 |
| Accart, N | 1 |
| Aubertin, G | 1 |
| Grellier, B | 1 |
| Erbs, P | 1 |
| Rooke, R | 1 |
| Constantinesco, A | 1 |
| Choquet, P | 1 |
| Chang, DY | 1 |
| Yoo, SW | 1 |
| Hong, Y | 1 |
| Kim, S | 1 |
| Kim, SJ | 1 |
| Yoon, SH | 1 |
| Cho, KG | 1 |
| Paek, SH | 1 |
| Lee, YD | 1 |
| Kim, SS | 1 |
| Suh-Kim, H | 1 |
| Jandl, G | 1 |
| Liszt, M | 1 |
| König-Schuster, M | 1 |
| Sedlak, J | 1 |
| Egerbacher, M | 1 |
| Weissenberger, J | 1 |
| Salmons, B | 1 |
| Günzburg, WH | 1 |
| Renner, M | 1 |
| Kim, HS | 1 |
| Jin, Y | 1 |
| Babic, M | 1 |
| Amundson, KK | 1 |
| Buckley, T | 1 |
| Galvão da Silva, AP | 1 |
| Lin, AH | 1 |
| Valenta, DT | 1 |
| Perez, OD | 1 |
| Chen, CI | 1 |
| Pettersson, PL | 1 |
| Daublebsky, V | 1 |
| Fei, S | 1 |
| Qi, X | 1 |
| Kedong, S | 1 |
| Guangchun, J | 1 |
| Jian, L | 1 |
| Wei, Q | 1 |
| Yi, BR | 1 |
| Kim, YB | 1 |
| Lee, HJ | 2 |
| Cho, MH | 1 |
| Choi, KC | 1 |
| Kosaka, H | 1 |
| Ichikawa, T | 3 |
| Kurozumi, K | 1 |
| Kambara, H | 1 |
| Inoue, S | 1 |
| Maruo, T | 1 |
| Nakamura, K | 1 |
| Hamada, H | 3 |
| Date, I | 1 |
| Wang, C | 1 |
| Natsume, A | 1 |
| Motomura, K | 1 |
| Nishimira, Y | 1 |
| Ohno, M | 1 |
| Ito, M | 1 |
| Kinjo, S | 1 |
| Momota, H | 1 |
| Iwami, K | 1 |
| Ohka, F | 1 |
| Wakabayashi, T | 1 |
| Barresi, V | 1 |
| Belluardo, N | 1 |
| Sipione, S | 1 |
| Mudò, G | 1 |
| Cattaneo, E | 1 |
| Condorelli, DF | 1 |
| Bourbeau, D | 1 |
| Lavoie, G | 1 |
| Nalbantoglu, J | 1 |
| Massie, B | 1 |
| Lü, SQ | 1 |
| Liu, YS | 1 |
| Wang, WJ | 1 |
| Kershaw, AD | 1 |
| Solly, SK | 1 |
| Klatzmann, D | 1 |
| Wei, J | 1 |
| Wahl, J | 1 |
| Knauss, H | 1 |
| Zeller, S | 1 |
| Jarmy, G | 1 |
| Fitze, G | 1 |
| Debatin, KM | 1 |
| Beltinger, C | 1 |
| Kaliberov, SA | 1 |
| Market, JM | 1 |
| Gillespie, GY | 2 |
| Krendelchtchikova, V | 1 |
| Della Manna, D | 1 |
| Sellers, JC | 1 |
| Kaliberova, LN | 1 |
| Black, ME | 1 |
| Buchsbaum, DJ | 2 |
| Choi, JD | 1 |
| Powers, CJ | 1 |
| Vredenburgh, JJ | 1 |
| Friedman, AH | 1 |
| Sampson, JH | 1 |
| Nishiyama, T | 2 |
| Kawamura, Y | 2 |
| Kawamoto, K | 2 |
| Matsumura, H | 2 |
| Yamamoto, N | 2 |
| Ito, T | 2 |
| Ohyama, A | 2 |
| Katsuragi, T | 2 |
| Sakai, T | 2 |
| Ge, K | 2 |
| Xu, L | 1 |
| Zheng, Z | 1 |
| Xu, D | 1 |
| Sun, L | 1 |
| Liu, X | 1 |
| Xu, LF | 1 |
| Zheng, ZC | 1 |
| Sun, LY | 1 |
| Liu, XY | 1 |
| Liao, WC | 1 |
| Chang, WS | 1 |
| Wu, FY | 1 |
| Wang, ZH | 1 |
| Zagzag, D | 1 |
| Zeng, B | 1 |
| Kolodny, EH | 1 |
| Adachi, Y | 2 |
| Tamiya, T | 2 |
| Terada, K | 1 |
| Ono, Y | 2 |
| Matsumoto, K | 2 |
| Furuta, T | 2 |
| Ohmoto, T | 2 |
| Yoshida, Y | 1 |
| Stegman, LD | 1 |
| Rehemtulla, A | 1 |
| Hamstra, DA | 1 |
| Rice, DJ | 1 |
| Jonas, SJ | 1 |
| Stout, KL | 1 |
| Chenevert, TL | 1 |
| Ross, BD | 1 |
| Chang, JW | 1 |
| Lee, H | 1 |
| Kim, E | 1 |
| Lee, Y | 1 |
| Chung, SS | 1 |
| Kim, JH | 1 |
| Noble, M | 1 |
| Miller, CR | 1 |
| Williams, CR | 1 |
| Kchir, N | 1 |
| Bouratbine, A | 1 |
| Boubaker, S | 1 |
| Jemel, H | 1 |
| Haouet, S | 1 |
| Chatti, S | 1 |
| Khaldi, M | 1 |
| Zitouna, MM | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Phase 2/3 Randomized, Open-Label Study of Toca 511, a Retroviral Replicating Vector, Combined With Toca FC Versus Standard of Care in Subjects Undergoing Planned Resection for Recurrent Glioblastoma or Anaplastic Astrocytoma[NCT02414165] | Phase 2/Phase 3 | 403 participants (Actual) | Interventional | 2015-11-30 | Terminated (stopped due to Sponsor Decision) | ||
| Phase I Study of Replication-Competent Adenovirus-Mediated Double Suicide Gene Therapy With Stereotactic Radiosurgery in Patients With Recurrent or Progressive High Grade Astrocytomas[NCT05686798] | Phase 1 | 18 participants (Anticipated) | Interventional | 2022-11-29 | Recruiting | ||
| A Phase 1 Ascending Dose Trial of Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered to Subjects at the Time of Resection for Recurrent High Grade Glioma & Followed by Treatment With Toca FC, Extended-Release 5-FC[NCT01470794] | Phase 1 | 58 participants (Actual) | Interventional | 2012-02-29 | Completed | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511 in Patients With Recurrent High Grade Glioma[NCT01156584] | Phase 1 | 54 participants (Actual) | Interventional | 2010-07-31 | Completed | ||
| A Phase 1 Ascending Dose Trial of the Safety and Tolerability of Toca 511, a Retroviral Replicating Vector, Administered Intravenously Prior to, and Intracranially at the Time of, Subsequent Resection for Recurrent HGG & Followed by Treatment With Extende[NCT01985256] | Phase 1 | 17 participants (Actual) | Interventional | 2014-02-28 | Completed | ||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
3 reviews available for flucytosine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Early clinical trials of Toca 511 and Toca FC show a promising novel treatment for recurrent malignant glioma.
Topics: Adult; Animals; Antineoplastic Combined Chemotherapy Protocols; Astrocytoma; Brain Neoplasms; Cytosi | 2019 |
Can neural stem cells be used to track down and destroy migratory brain tumor cells while also providing a means of repairing tumor-associated damage?
Topics: Animals; Brain Neoplasms; Cell Movement; Combined Modality Therapy; Cytosine Deaminase; Flucytosine; | 2000 |
[Cerebral aspergillotic granuloma. Apropos of a case and a review of the literature].
Topics: Adult; Aged; Amphotericin B; Aspergillosis; Brain Diseases; Brain Neoplasms; Child; Diagnosis, Diffe | 1990 |
3 trials available for flucytosine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Molecular and Immunologic Signatures are Related to Clinical Benefit from Treatment with Vocimagene Amiretrorepvec (Toca 511) and 5-Fluorocytosine (Toca FC) in Patients with Glioma.
Topics: Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Biomarkers, Tumor; Brain Neoplasms; Cyt | 2020 |
Effect of Vocimagene Amiretrorepvec in Combination With Flucytosine vs Standard of Care on Survival Following Tumor Resection in Patients With Recurrent High-Grade Glioma: A Randomized Clinical Trial.
Topics: Aged; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; Bevacizumab; Brain Neop | 2020 |
Durable complete responses in some recurrent high-grade glioma patients treated with Toca 511 + Toca FC.
Topics: Antimetabolites; Brain Neoplasms; Combined Modality Therapy; Cytosine Deaminase; Drug Synergism; Flu | 2018 |
43 other studies available for flucytosine and Benign Neoplasms, Brain
| Article | Year |
|---|---|
Efficient Prodrug Activator Gene Therapy by Retroviral Replicating Vectors Prolongs Survival in an Immune-Competent Intracerebral Glioma Model.
Topics: Animals; Aziridines; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Escherichia coli Protein | 2020 |
Toca 511 gene transfer and treatment with the prodrug, 5-fluorocytosine, promotes durable antitumor immunity in a mouse glioma model.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Disease Model | 2017 |
Isocytosine deaminase Vcz as a novel tool for the prodrug cancer therapy.
Topics: Adenocarcinoma; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Caco-2 Cells; Cell Line, | 2019 |
Convection-enhanced delivery improves distribution and efficacy of tumor-selective retroviral replicating vectors in a rodent brain tumor model.
Topics: Animals; Brain Neoplasms; Convection; Cytosine Deaminase; Drug Delivery Systems; Flucytosine; Geneti | 2013 |
Combined alloreactive CTL cellular therapy with prodrug activator gene therapy in a model of breast cancer metastatic to the brain.
Topics: Adenoviridae; Animals; Brain Neoplasms; Breast Neoplasms; Combined Modality Therapy; Cytosine Deamin | 2013 |
Adenosine potentiates the therapeutic effects of neural stem cells expressing cytosine deaminase against metastatic brain tumors.
Topics: Adenosine; Animals; Antimetabolites, Antineoplastic; Apoptosis; Blood-Brain Barrier; Blotting, Weste | 2013 |
Lentivirus-mediated CD/TK fusion gene transfection neural stem cell therapy for C6 glioblastoma.
Topics: Animals; Antimetabolites; Antineoplastic Combined Chemotherapy Protocols; Antiviral Agents; Apoptosi | 2013 |
Neural stem cell-mediated enzyme/prodrug therapy for glioma.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Glioma; Humans; Mi | 2013 |
Toca 511 gene transfer and 5-fluorocytosine in combination with temozolomide demonstrates synergistic therapeutic efficacy in a temozolomide-sensitive glioblastoma model.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Dacarb | 2013 |
Complete regression of glioblastoma by mesenchymal stem cells mediated prodrug gene therapy simulating clinical therapeutic scenario.
Topics: Adipose Tissue; Animals; Antimetabolites; Bone Marrow; Brain Neoplasms; Cell Proliferation; Cells, C | 2014 |
Intravenous administration of retroviral replicating vector, Toca 511, demonstrates therapeutic efficacy in orthotopic immune-competent mouse glioma model.
Topics: Animals; Antibodies, Neutralizing; Antimetabolites; Brain Neoplasms; Clinical Trials as Topic; Cytos | 2015 |
Toca 511 plus 5-fluorocytosine in combination with lomustine shows chemotoxic and immunotherapeutic activity with no additive toxicity in rodent glioblastoma models.
Topics: Animals; Antineoplastic Combined Chemotherapy Protocols; Brain Neoplasms; Cytosine Deaminase; Diseas | 2016 |
"Tag Team" Glioblastoma Therapy: Results From a Phase 1 Trial of Toca 511 and 5-Fluorocytosine for Recurrent High-Grade Glioma.
Topics: Brain Neoplasms; Flucytosine; Glioblastoma; Glioma; Humans | 2016 |
Human neural stem cells can target and deliver therapeutic genes to breast cancer brain metastases.
Topics: Animals; Brain Neoplasms; Breast Neoplasms; Cell Line; Cell Proliferation; Cell Survival; Coculture | 2009 |
In vivo preclinical low-field MRI monitoring of tumor growth following a suicide-gene therapy in an orthotopic mice model of human glioblastoma.
Topics: Animals; Antimetabolites, Antineoplastic; Biotransformation; Brain Neoplasms; Cytosine Deaminase; Fe | 2010 |
The growth of brain tumors can be suppressed by multiple transplantation of mesenchymal stem cells expressing cytosine deaminase.
Topics: Adolescent; Animals; Brain Neoplasms; Bystander Effect; Child; Chromatography, High Pressure Liquid; | 2010 |
Comparative evaluation of preclinical in vivo models for the assessment of replicating retroviral vectors for the treatment of glioblastoma.
Topics: Animals; Brain Neoplasms; Bystander Effect; Cytosine Deaminase; Disease Models, Animal; Drug Evaluat | 2011 |
Combined treatment of tumor-tropic human neural stem cells containing the CD suicide gene effectively targets brain tumors provoking a mild immune response.
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cell Movement; Combined Modality Therapy; Cytosine | 2011 |
Human adipose tissue-derived mesenchymal stem cells expressing yeast cytosinedeaminase::uracil phosphoribosyltransferase inhibit intracerebral rat glioblastoma.
Topics: Adipose Tissue; Animals; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy; Cytosine Deam | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
Brain tumor eradication and prolonged survival from intratumoral conversion of 5-fluorocytosine to 5-fluorouracil using a nonlytic retroviral replicating vector.
Topics: Animals; Brain Neoplasms; Combined Modality Therapy; Disease Models, Animal; Female; Flucytosine; Fl | 2012 |
The antitumor effect of mesenchymal stem cells transduced with a lentiviral vector expressing cytosine deaminase in a rat glioma model.
Topics: Animals; Apoptosis; Brain Neoplasms; Cell Line, Tumor; Cytosine Deaminase; Flucytosine; Genetic Ther | 2012 |
Antitumor effects of genetically engineered stem cells expressing yeast cytosine deaminase in lung cancer brain metastases via their tumor-tropic properties.
Topics: Animals; Brain Neoplasms; Cell Survival; Cytosine Deaminase; Flucytosine; Fluorouracil; Genetic Engi | 2012 |
Therapeutic effect of suicide gene-transferred mesenchymal stem cells in a rat model of glioma.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Coculture Techniques; Cytosine Deaminase; | 2012 |
Neural stem cell-based dual suicide gene delivery for metastatic brain tumors.
Topics: Administration, Intravenous; Animals; Antineoplastic Agents; Brain Neoplasms; Bystander Effect; Caro | 2012 |
Transplantation of prodrug-converting neural progenitor cells for brain tumor therapy.
Topics: Animals; Brain Neoplasms; Cells, Cultured; Cytosine Deaminase; Escherichia coli; Flucytosine; Fluoro | 2003 |
Suicide gene therapy with an adenovirus expressing the fusion gene CD::UPRT in human glioblastomas: different sensitivities correlate with p53 status.
Topics: Adenoviridae; Antimetabolites; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Gene Expression Pro | 2004 |
[Effects of CD/5-FC suicide gene therapy system on human malignant glioma cells in vitro].
Topics: Brain Neoplasms; Cytosine Deaminase; Flucytosine; Fluorouracil; Gene Transfer Techniques; Genetic Th | 2004 |
Single-shot, multicycle suicide gene therapy by replication-competent retrovirus vectors achieves long-term survival benefit in experimental glioma.
Topics: Animals; Antimetabolites; Brain Neoplasms; Cell Line, Tumor; Flucytosine; Genes, Transgenic, Suicide | 2005 |
Use of replication-competent retroviral vectors in an immunocompetent intracranial glioma model.
Topics: Animals; Brain Neoplasms; Cell Line, Tumor; Cell Survival; Disease Models, Animal; DNA, Viral; Encep | 2006 |
Cytosine deaminase/5-fluorocytosine gene therapy and Apo2L/TRAIL cooperate to kill TRAIL-resistant tumor cells.
Topics: Animals; Apoptosis; Brain Neoplasms; Caspases; Cell Division; Cell Line, Tumor; Cloning, Molecular; | 2007 |
Mutation of Escherichia coli cytosine deaminase significantly enhances molecular chemotherapy of human glioma.
Topics: Adenoviridae; Animals; Antimetabolites; Brain Neoplasms; Cell Line, Tumor; Combined Modality Therapy | 2007 |
Cryptococcal meningitis in patients with glioma: a report of two cases.
Topics: Adult; Aged; Amphotericin B; Anti-Inflammatory Agents; Antifungal Agents; Antineoplastic Agents, Alk | 2008 |
[Antineoplastic effect of 5-fluorocytosine and cytosine deaminase on brain tumor (author's transl)].
Topics: Animals; Antineoplastic Agents; Brain Neoplasms; Cytosine; Cytosine Deaminase; Drug Therapy, Combina | 1982 |
Transduction of cytosine deaminase gene makes rat glioma cells highly sensitive to 5-fluorocytosine.
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Drug Resistance, Neop | 1997 |
[Experimental treatment of brain tumor cells using CD suicide gene].
Topics: Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Escherichia coli; Flu | 1996 |
Re: Synergistic anticancer effects of ganciclovir/thymidine kinase and 5-fluorocytosine/cytosine deaminase gene therapies.
Topics: Animals; Antimetabolites, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Antiviral | 1999 |
In vivo and in vitro glioma cell killing induced by an adenovirus expressing both cytosine deaminase and thymidine kinase and its association with interferon-alpha.
Topics: Adenoviridae; Animals; Antineoplastic Agents; Apoptosis; Brain; Brain Neoplasms; Cell Survival; Cyto | 1999 |
Experimental gene therapy for brain tumors using adenovirus-mediated transfer of cytosine deaminase gene and uracil phosphoribosyltransferase gene with 5-fluorocytosine.
Topics: Adenoviridae; Animals; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Gene Transfer Techniques; G | 2000 |
In vivo efficacy and toxicity of 5-fluorocytosine/cytosine deaminase gene therapy for malignant gliomas mediated by adenovirus.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Brain; Brain Neoplasms; Cytosine Deaminase; | 2000 |
Diffusion MRI detects early events in the response of a glioma model to the yeast cytosine deaminase gene therapy strategy.
Topics: Animals; Antifungal Agents; Brain Neoplasms; Cytosine Deaminase; Flucytosine; Genetic Therapy; Gliom | 2000 |
Combined antitumor effects of an adenoviral cytosine deaminase/thymidine kinase fusion gene in rat C6 glioma.
Topics: Adenoviridae; Animals; Antimetabolites; Antiviral Agents; Artificial Gene Fusion; Brain Neoplasms; C | 2000 |
Intratumoral 5-fluorouracil produced by cytosine deaminase/5-fluorocytosine gene therapy is effective for experimental human glioblastomas.
Topics: Adenoviridae; Animals; Antimetabolites, Antineoplastic; Brain Neoplasms; Cytosine Deaminase; Flucyto | 2002 |
Antineoplastic effects in rats of 5-fluorocytosine in combination with cytosine deaminase capsules.
Topics: Animals; Brain Neoplasms; Capsules; Cytosine; Cytosine Deaminase; Drug Evaluation, Preclinical; Drug | 1985 |